½ÃÀ庸°í¼­
»óǰÄÚµå
1416195

½ÉÀåÀ絿±âÈ­¿ä¹ý(CRT) ±â±â ½ÃÀå : Á¦Ç°º°, ¿¬·Éº°, ÃÖÁ¾ ¿ëµµº° Àü¸Á(2023-2032³â)

Cardiac Resynchronisation Therapy (CRT) Devices Market - By Product (CRT-P, CRT-D), By Age (Below 44 Years, 45- 64 Years, 65-84 Years, Above 85 Years), By End-use & Forecast, 2023 - 2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Global Market Insights Inc. | ÆäÀÌÁö Á¤º¸: ¿µ¹® 230 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°è ½ÉÀåÀ絿±âÈ­¿ä¹ý(CRT) ±â±â ½ÃÀåÀº ÀÇ·á ±â¼ú ¹ßÀü, ½ÉºÎÀü À¯º´·ü Áõ°¡, ȯÀÚ ¹× ÀÇ·áÁøÀÇ ÀÎ½Ä Á¦°í µîÀ» ¹è°æÀ¸·Î 2023³âºÎÅÍ 2032³â±îÁö 5.9%ÀÇ ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

Radcliffe Cardiology°¡ 2023³â¿¡ ¹ßÇ¥ÇÑ ¿¬±¸¿¡ µû¸£¸é, ½ÉºÎÀü(HF)Àº Àü ¼¼°èÀûÀ¸·Î ¾à 6400¸¸ ¸íÀÌ ¾Î°í ÀÖ´Â °ÍÀ¸·Î ÃßÁ¤µÇ´Â ¼¼°è °øÁߺ¸°Ç ¹®Á¦ÀÔ´Ï´Ù. °í·ÉÈ­À²ÀÌ Áõ°¡ÇÏ°í »ýȰ ½À°üÀÌ ½ÉÀå °ü·Ã ¹®Á¦¸¦ À¯¹ßÇÏ´Â ¿äÀÎÀÌ µÇ¸é¼­ °í±Þ ½ÉÀå °ü¸® ¼Ö·ç¼ÇÀÇ Çʿ伺ÀÌ ´õ¿í ºÎ°¢µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ½ÉÀå À絿±âÈ­ Ä¡·áÀÇ ÀÌÁ¡¿¡ ´ëÇÑ ÀÇ·á Àü¹®°¡¿Í ȯÀÚÀÇ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ¾÷°è ¼ºÀå¿¡ ´õ¿í ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù.

¼¼°è CRT ÀåÄ¡ ½ÃÀåÀº Á¦Ç°, ÃÖÁ¾ ¿ëµµ ¹× Áö¿ªº°·Î ºÐ·ùµË´Ï´Ù.

CRT ½É¹ÚÁ¶À²±â ºÐ¾ß´Â ½ÉÀå µ¿±âÈ­ °­È­, ÆäÀÌ½Ì ¹× À絿±âÈ­ ÀÌÁß ±â´É, ±â¼ú ¹ßÀüÀ¸·Î ÀÎÇØ Á¶»ç ±â°£ µ¿¾È ¾ÈÁ¤ÀûÀÎ ¼Óµµ·Î È®´ëµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÆäÀ̰̽ú À絿±âÈ­ ¿ä±¸¸¦ ¸ðµÎ ÃæÁ·ÇÏ´Â ÀÌÁß ±â´ÉÀº º¹ÀâÇÑ ½ÉÀå Ä¡·á ¼ö¿ä¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ¼Ö·ç¼ÇÀ¸·Î ÀÚ¸®¸Å±èÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ °í±Þ ½ÉÀå °ü¸® ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡´Â Á¦Ç° ¼ö¿ä¸¦ ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

½ÉÀå Ä¡·á ¼¾ÅÍÀÇ ÃÖÁ¾ ¿ëµµ ºÐ¾ß´Â Á¾ÇÕÀûÀÎ ½ÉÀå Ä¡·á ¼­ºñ½º¿Í ¿ª·® °­È­·Î 2032³â±îÁö ²ÙÁØÇÑ ¼ºÀå ¸ð¸àÅÒÀ» À¯ÁöÇϰí ÀÖ½À´Ï´Ù. ½ÉÀå Ä¡·á ¼¾Åʹ ȯÀÚ Áß½ÉÀÇ °³º° Ä¡·á¸¦ ¿ì¼±½ÃÇÏ¿© ÀÇ·á ºÐ¾ß¿¡¼­ ¸Å·ÂÀ» ³ôÀ̰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¿ø°Ý ÀÇ·á ¹× ¿ø°Ý ¸ð´ÏÅ͸µ ±â¼úÀ» ½ÉÀå Ä¡·á ¼¾ÅÍ¿¡ ÅëÇÕÇÏ¿© Á¢±Ù¼ºÀ» ³ôÀ̰í ȯÀÚ °á°ú¸¦ °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù.

¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ½ÉÀå À絿±âÈ­ Ä¡·á ±â±â ½ÃÀåÀº 2023³âºÎÅÍ 2032³â±îÁö °­·ÂÇÑ ¼ºÀå¼¼¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ´Â Áß±¹, Àεµ¿Í °°Àº ±¹°¡¿¡¼­ ÀÇ·á ÀÎÇÁ¶óÀÇ È®´ë¿Í ÇÔ²² ½ÉÇ÷°ü ÁúȯÀÇ ¹ßº´·üÀÌ Áõ°¡Çϰí Àֱ⠶§¹®ÀÔ´Ï´Ù. ÀÌ Áö¿ª¿¡¼­´Â ÇコÄÉ¾î ºÐ¾ßÀÇ ±Þ¼ÓÇÑ ±â¼ú ¹ßÀüÀÌ ÀÌ·ç¾îÁö°í ÀÖÀ¸¸ç, ÀÌ ºÐ¾ß¿¡ À¯¸®ÇÑ È¯°æÀÌ Á¶¼ºµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÇ·á ½Ã½ºÅÛÀÌ È¯ÀÚ °á°ú °³¼±¿¡ ÃÊÁ¡À» ¸ÂÃß°í Àֱ⠶§¹®¿¡ R&D ÀÌ´Ï¼ÅÆ¼ºê¿¡ ´ëÇÑ ÀÚ±ÝÀÌ ½ÃÀå Àü¸ÁÀ» Çü¼ºÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú Á¶»ç ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÉÀåÀ絿±âÈ­ ¿ä¹ý ±â±â ¾÷°è ÀλçÀÌÆ®

  • »ýÅÂ°è ºÐ¼®
  • ¾÷°è¿¡ ´ëÇÑ ¿µÇâ¿äÀÎ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¾÷°èÀÇ ÀáÀçÀû ¸®½ºÅ©£¦°úÁ¦
  • ¼ºÀå °¡´É¼º ºÐ¼®
  • COVID-19ÀÇ ¿µÇ⠺м®
  • ±ÔÁ¦ »óȲ
    • ¹Ì±¹
    • À¯·´
  • »óȯ ½Ã³ª¸®¿À
  • ±â¼ú Àü¸Á
  • ÇâÈÄ ½ÃÀå µ¿Çâ
  • Porter's Five Forces ºÐ¼®
  • °¸ ºÐ¼®
  • PESTEL ºÐ¼®

Á¦4Àå °æÀï ±¸µµ

  • ¼­·Ð
  • ±â¾÷ ¸ÅÆ®¸¯½º ºÐ¼®
  • ±â¾÷ Á¡À¯À² ºÐ¼®
  • °æÀï Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º
  • º¥´õ¡¤¸ÅÆ®¸¯½º ºÐ¼®
  • Àü·« ´ë½Ãº¸µå

Á¦5Àå ½ÉÀåÀ絿±âÈ­ ¿ä¹ý ±â±â ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : Á¦Ç°º°

  • ÁÖ¿ä ±â¼ú µ¿Çâ
  • CRT ÆäÀ̽º¸ÞÀÌÄ¿
    • MRI ´ëÀÀ CRT-P µð¹ÙÀ̽º
    • ±âÁ¸ CRT-P µð¹ÙÀ̽º
  • CRT-Á¦¼¼µ¿±â
    • MRI ´ëÀÀ CRT-D
    • ±âÁ¸ CRT-D ±â±â

Á¦6Àå ½ÉÀåÀ絿±âÈ­ ¿ä¹ý ±â±â ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : ¿¬·Éº°

  • ÁÖ¿ä ¿¬·É µ¿Çâ
  • 44¼¼ ÀÌÇÏ
  • 45-64¼¼
  • 65-84¼¼
  • 85¼¼ ÀÌ»ó

Á¦7Àå ½ÉÀåÀ絿±âÈ­ ¿ä¹ý ±â±â ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : ÃÖÁ¾ ¿ëµµº°

  • ÁÖ¿ä ÃÖÁ¾»ç¿ëÀÚ µ¿Çâ
  • º´¿ø
  • ½ÉÀåÄ¡·á¼¾ÅÍ
  • ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC)

Á¦8Àå ½ÉÀåÀ絿±âÈ­ ¿ä¹ý ±â±â ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : Áö¿ªº°

  • ÁÖ¿ä Áö¿ª µ¿Çâ
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ÀÌÅ»¸®¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • Çѱ¹
    • È£ÁÖ
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ¾Æ¸£ÇîÆ¼³ª
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
    • ±âŸ MEA

Á¦9Àå ±â¾÷ °³¿ä

  • Medtronic PLC
  • Abbott Laboratories
  • Biotronik
  • Boston Scientific Corporation
  • Microport Scientific Corporation
  • Medico S.p.A
  • LivaNova PLC
LSH 24.02.05

The global Cardiac Resynchronization Therapy (CRT) Devices Market is anticipated to expand at 5.9% during 2023-2032, driven by advancements in medical technology, increasing prevalence of heart failure, and growing awareness amongst patients & healthcare professionals.

According to a study published by Radcliffe Cardiology in 2023, Heart failure (HF) is an escalating global public health concern, affecting an estimated 64 million people worldwide. As the aging population proportion grows and lifestyle factors contribute to heart-related issues, the need for advanced cardiac care solutions becomes more pronounced. Additionally, the growing awareness among healthcare professionals and patients about the benefits of cardiac resynchronization therapy further fuels industry growth.

The global CRT devices market is classified based on product, end-use, and region.

The CRT-pacemakers segment is expected to expand at a steady pace during the study period driven by enhanced cardiac synchronization, dual functionality in pacing & resynchronization and technological advancements. The dual functionality, addressing both pacing and resynchronization needs, positions them as comprehensive solutions for the intricate demands of cardiac care. Moreover, the growing demand for advanced cardiac care solutions has further propelled product demand.

Cardiac care centers end-use segment is gaining momentum for steady growth through 2032, driven by comprehensive cardiac care services and capability enhancement. Cardiac care centers prioritize individualized, patient-centric care, boosting their appeal in the healthcare sector. Moreover, the integration of telemedicine and remote monitoring technologies in cardiac care centers enhances accessibility and improves patient outcomes.

Asia Pacific cardiac resynchronization therapy devices market is set for robust growth during 2023 and 2032, attributed to the increasing incidence of cardiovascular diseases, coupled with the expanding healthcare infrastructure in countries like China and India. The region is witnessing rapid technological advancements in the healthcare sector, creating a conducive environment for the sector. Moreover, as healthcare systems focus on improving patient outcomes, the funding for R&D initiatives will shape the market outlook.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Industry coverage
  • 1.2 Market scope & definitions
  • 1.3 Base estimates & working
    • 1.3.1 Data collection
  • 1.4 Forecast parameters
  • 1.5 COVID-19 impact at global level
  • 1.6 Data validation
  • 1.7 Data sources
    • 1.7.1 Primary
    • 1.7.2 Secondary
      • 1.7.2.1 Paid sources
      • 1.7.2.2 Unpaid sources

Chapter 2 Executive Summary

  • 2.1 Cardiac resynchronisation therapy devices industry 360 degree synopsis, 2018 - 2032
  • 2.2 Business trends
  • 2.3 Regional trends
  • 2.4 Product trends
  • 2.5 Age trends
  • 2.6 End-use

Chapter 3 Cardiac Resynchronisation Therapy Devices Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Growing incidence of cardiovascular disorders
      • 3.2.1.2 Increasing geriatric population
      • 3.2.1.3 Technological advancements
      • 3.2.1.4 Favorable reimbursement scenario
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 High cost of CRT devices
      • 3.2.2.2 Stringent regulatory scenario
  • 3.3 Growth potential analysis
    • 3.3.1 By product
    • 3.3.2 By age
    • 3.3.3 By end-use
  • 3.4 COVID-19 impact analysis
  • 3.5 Regulatory landscape
    • 3.5.1 U.S.
    • 3.5.2 Europe
  • 3.6 Reimbursement scenario
  • 3.7 Technology landscape
  • 3.8 Future market trends
  • 3.9 Porter's analysis
  • 3.10 Gap analysis
  • 3.11 PESTEL analysis

Chapter 4 Competitive Landscape, 2022

  • 4.1 Introduction
  • 4.2 Company matrix analysis, 2022
  • 4.3 Company market share analysis, 2022
  • 4.4 Competitive positioning matrix
  • 4.5 Vendor matrix analysis
  • 4.6 Strategy dashboard, 2022

Chapter 5 Cardiac Resynchronisation Therapy Devices Market Size and Forecast, By Product (USD Million & Units)

  • 5.1 Key technology trends
  • 5.2 CRT-Pacemakers
    • 5.2.1 MRI Compatible CRT-P Devices
    • 5.2.2 Conventional CRT-P Devices
  • 5.3 CRT-Defibrillators
    • 5.3.1 MRI Compatible CRT-D Devices
    • 5.3.2 Conventional CRT-D Devices

Chapter 6 Cardiac Resynchronisation Therapy Devices Market Size and Forecast, By Age (USD Million)

  • 6.1 Key age trends
  • 6.2 Below 44 years
  • 6.3 45-64 years
  • 6.4 65-84 years
  • 6.5 Above 85 years

Chapter 7 Cardiac Resynchronisation Therapy Devices Market Size and Forecast, By End-use (USD Million)

  • 7.1 Key end-use trends
  • 7.2 Hospitals
  • 7.3 Cardiac care centers
  • 7.4 Ambulatory surgical centers

Chapter 8 Cardiac Resynchronisation Therapy Devices Market Size and Forecast, By Region (USD Million)

  • 8.1 Key regional trends
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 France
    • 8.3.4 Spain
    • 8.3.5 Italy
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 South Korea
    • 8.4.5 Australia
    • 8.4.6 Rest of Asia Pacific
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Mexico
    • 8.5.3 Argentina
    • 8.5.4 Rest of Latin America
  • 8.6 Middle East & Africa
    • 8.6.1 South Africa
    • 8.6.2 Saudi Arabia
    • 8.6.3 UAE
    • 8.6.4 Rest of MEA

Chapter 9 Company Profiles

  • 9.1 Medtronic PLC
  • 9.2 Abbott Laboratories
  • 9.3 Biotronik
  • 9.4 Boston Scientific Corporation
  • 9.5 Microport Scientific Corporation
  • 9.6 Medico S.p.A
  • 9.7 LivaNova PLC
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦